HANEY CECIL D sold $361K of THC

Sutaria Saumya (CEO) sold 100,000 shares of TENET HEALTHCARE CORP (THC) at an average of $276.36 ($273.34–$278.90, $27.64M total) across 5 trades over 2026-08-24 to 2026-08-25.

Medtronic (MDT) and Tenet Healthcare (THC) present distinct growth prospects. MDT reported its highest annual revenue growth in a decade, driven by cardiac ablation solutions and investments in innovation. THC saw a 52.2% increase in adjusted EPS and 6.8% revenue growth, with margin expansion in hospitals. Investors must choose between MDT's innovation-led recovery and THC's operational improvements.

Tenet Healthcare (THC) stock hit an all-time high of $270.79, up 54.4% over the past year. The company reported strong Q2 2026 earnings, exceeding expectations with $6.12 EPS on $5.63B revenue. Analysts raised price targets, with UBS setting the highest at $308. THC's P/E ratio is 10.46, and PEG ratio is 0.15, suggesting attractive valuation.

Tenet Healthcare (NYSE:THC) reported fiscal Q2 2026 results that beat estimates and raised its full-year outlook. Adjusted EPS rose 52.2% to $6.12 and net operating revenue increased 6.8% to $5.63B. Hospital adjusted EBITDA margin expanded to 18.0%. Guidance: adjusted EBITDA $4.83B-$5.03B and net operating revenue $21.9B-$22.5B.

More and more uninsured patients are showing up in hospital emergency rooms and clinics, having lost their coverage under the Affordable Care Act. Executives running some of the biggest hospital systems, including large for-profit chains spanning many states, expressed concern over the unexpectedly sharp rise in uninsured patients and the costs associated with treating them.

Tenet Healthcare raised 2026 guidance after Q2 headwinds on Affordable Care Act exchanges. The company now expects adjusted EBITDA of $4.8B to $5.0B, up from $4.5B to $4.8B. Q2 net income rose to $826M on $5.6B revenue, though ACA revenue fell $65M as ACA admissions declined.